More good news on the world-wide expansion of support services for WM patients comes from Downunder Australia.
The IWMF’s newest International Affiliate, WM-España, is based in Navarra, Spain under the leadership of Miguel Angel Berrueta.
The Amyloidosis Foundation is offering a free, one hour webinar on March 16th from 4:00-5:00 EST. This seminar will be conducted by Dr. Morie Gertz of the Mayo Clinic.
From February 27 to March 1, the Lymphoma Coalition (LC), an international network of lymphoma patient groups that includes the IWMF, will be running an ad in USA Today.
IWMF President and WM patient Carl Harrington has written an article entitled “What To Do When Diagnosed With a Rare Cancer,"
The IWMF’s newest International Affiliate, Macroglobulinemia De Waldenstrom Argentina, is based in Buenos Aires, Argentina, under the leadership of Graciela Silvia Molina, MD.
To provide the latest news on advances in WM research and treatments, and up-to-the minute information on our services to members, the IWMF will use both Facebook and Twitter.
Oncology Nursing News magazine interviewed Carl Harrington, president of the IWMF, about the US FDA's decision to approve imbruvica (ibrutinib).
Cure magazine (http://www.curetoday.com) interviewed Carl Harrington, president of the IWMF, to properly present the impact that the US FDA's decision to approve imbruvica (ibrutinib) specifically for WM has on WM patients. He also discusses the significance of the IWMF in providing support to WM patients and in funding research.
The complete article is at: http://tinyurl.com/iwmf-ibrutinib
In a history-making moment for WM patients, the IWMF is pleased to announce that Imbruvica (ibrutinib) has just received FDA approval specifically for the treatment of WM, thus becoming the first drug therapy to achieve this designation.